TABLE 1.

Patients characteristics and clinical evaluation of effectiveness.

	Baseline	Week 12	Week 24
Age, Median (range) years	53 (35–73)
% of female	73%
Disease duration, mean (range) years	8 (2–28)
RF positive	59
ACPA positive	55
RF positive/ACPA positive	55
RF positive/ACPA negative	11
RF negative/ACPA negative	14
Concomitant DMARD (patients)	60 TCZ, 20 ADA
Concomitant Steroid (patients)	36 TCZ, 11 ADA
Number of Previous DMARD	3 (Methotrexate, Leflunomide, Azathioprine)
Patients with Rituximab therapy	0
Patients completed the TCZ study	60	58	53
Patients completed the ADA study	20	20	19
Tocilizumab (n = 60)	n = 60	n = 58	n = 53
DAS28 score (mean ± SD)	5.16 ± 1.31	3.22 ± 1.31ψ	2.65 ± 1.22ψ
CRP, mg/dl (mean ± SEM)	0.59 ± 0.09	0.14 ± 0.05ψ	0.08 ± 0.03ψ
ESR, mm/hour (mean ± SEM)	29.41 ± 3.15	9.06 ± 1.30ψ	7.11 ± 0.84 ψ
Patient’s VAS. (mean ± SEM)	58.21 ± 4.16	46.97 ± 4.21 ψ	33.21 ± 4.74 ψ
Adalimumab (n = 20)	n = 20	n = 20	n = 19
DAS28 score (mean ± SD)	4.78 ± 0.9	2.43 ± 0.71 ψ	1.91 ± 0.61 ψ
CRP, mg/dl (mean ± SEM)	0.88 ± 0.4	0.25 ± 0.05ψ	0.12 ± 0.04 ψ
ESR, mm/hour (mean ± SEM)	26.67 ± 6.1	12.86 ± 3.3ψ	8.57 ± 1.7 ψ
Patient’s VAS (mean ± SEM)	57.14 ± 7.3	26.43 ± 7.5 ψ	19.29 ± 2.9 ψ

The primary endpoint of the study was a reduction in the Disease Activity Score in 28 joints (DAS28) at week 24. Except where indicated, values are the mean ± SEM. RF, rheumatoid factor; ACPA, anti-citrullinated peptide/protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; and VAS, visual analog scale (100-mm). ^ΨP < 0.05 vs baseline.